MDT

Medtronic plc

Fundamental data last updated:July 9, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/18/2026

Business Summary

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

 


VALUATION

P/E

21.90

Market Cap ($M USD)

$104.98B

Forward P/E

9.97

PEG

0.08

PRICE TO SALES

2.89

PRICE TO BOOK

2.13

EV / EBITDA

13.48

5-Year Average P/E

Free Cash Flow Yield

5.17%

DCF Value

$200.96

Graham Number

$57.02

Price to FCF

19.35

EV to FCF

24.14

Earnings Yield

4.57%

FCF Yield

5.17%

DIVIDEND

Yield

3.48%

Annual Payout

$2.85

Payout Ratio

75.81%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$3.74

Next Year EPS Growth Estimate

$8.23

Next Year Revenue Growth Estimate

$4.66T

Return on Equity (ROE)

9.85%

FREE CASH FLOW

Operating Margin

17.78%

Debt-to-Equity

0.57

Piotroski F-Score

8

Altman Z-Score

2.77

Return on Invested Capital (ROIC)

7.95%

Current Ratio

2.13

Quick Ratio

1.62

Net Debt to EBITDA

2.68

Interest Coverage

9.04

Gross Profit margin

65.02%

FCF PER SHARE

$4.23

REVENUE PER SHARE

$28.37

Gainseekers Quantitative Analysis

Summary

Equinix’s valuation is a paradox of extremes. Despite a staggering Price/Earnings ratio of 75.56, the market seems to have priced it well above its DCF Value and Graham Number, suggesting a potential overvaluation. Yet, the Forward P/E of 40.39 and a PEG ratio of 0.46 hint at anticipated growth, aligning with a robust Altman Z-score of 3.04, indicating financial stability. The Earnings Yield of 1.32% is underwhelming, raising questions about the stock’s immediate income potential. Overall, while the market cap reflects confidence, the valuation metrics suggest caution.

AI Exposure / Tech Reliance

Operating within the REIT - Specialty sector, Equinix is uniquely positioned to leverage AI and tech advancements. Its infrastructure supports digital ecosystems, making it a critical player in the data center space. This positioning allows it to adapt swiftly to technological shifts, ensuring resilience in a rapidly evolving landscape.

The Bull Case

For the discerning GARP investor, Equinix offers compelling institutional tailwinds. With a solid ROIC of 5.41% and a Piotroski F-Score of 5, the company demonstrates efficient capital use and moderate financial health. Its Operating Margin of 20.80% underscores strong pricing power, while the FCF Yield, though low, indicates potential for future cash flow improvements. These metrics paint a picture of a company with the ability to generate consistent returns despite its high valuation.

The Bear Case

However, the bear case is hard to ignore. Equinix's Price/Book ratio of 7.51 and Price/Sales of 11.39 are alarmingly high, suggesting the stock is priced for perfection. The Price to FCF ratio of 121.29 and EV to FCF of 146.00 highlight significant cash flow challenges. Additionally, trading just 3.36% below its 52-week high, the stock appears technically overextended, raising concerns about its current valuation sustainability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$95.73

Institutional Ownership %

1-Year Beta

0.58

Insider Buying % (6 Mo)

Distance to 52-Week High

29.65%

Distance to 52-Week Low

10.61%

EARNINGS SURPRISE %

0.65%

50-DAY SMA

$79.05

200-DAY SMA

$91.22

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.